TTA-A2

Research use only, not for human use.

TTA-A2 is a selective T-type calcium channel antagonist as a potent anticonvulsant that the Cav3.1 isoform plays a prominent role in mediating.

TTA-A2 is a selective T-type calcium channel antagonist as a potent anticonvulsant that the Cav3.1 isoform plays a prominent role in mediating. TTA-A2 is equally potent against the Cav3.1 (a1G) and Cav3.2 (a1H) channels with IC50 values of 89 nM and 92 nM, respectively, at -80 and -100 mV holding potentials. TTA-A2 can be used for the research of a variety of human neurological diseases, including sleep disorders and epilepsy.

——

Animal Model:Wild-type and double Cav3.1/Cav3.3 knockout C57BL6/Sv129 background mices Dosage:10?mg/kg Administration:Oral gavage; 10?mg/kg; once daily; 5 days Result:Blocked active wake and promotes slow-wave sleep in wild-type mice but not mutant mice.

——

GPCR/G Protein

Calcium Channel

Cav3.1 (a1G)|Cav3.2 (a1H)

——

——

953778-63-7

378.4

C20H21F3N2O2

>98% (HPLC)

DMSO:10 mM

C[C@H](C1=NC=C(C=C1)OCC(F)(F)F)NC(=O)CC2=CC=C(C=C2)C3CC3

——

(-20℃)

With Ice Pack

≥ 2 years